Asset Details
Do you wish to reserve the book?
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”
Do you wish to request the book?
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”
2024
Overview
[...]Hu et al. rightly point out the potential influence of infections on the symptoms of PPP. [...]the smoking status of patients included in the trial was questioned. [...]Hu et al. emphasise the importance of genetic testing of patients with PPP when evaluating the efficacy of spesolimab. To explore the impact of these mutations on the efficacy of spesolimab treatment, subgroup analysis by gene mutation status was performed on the primary and secondary endpoints; however, due to the low numbers of patients with a genetic mutation, these efficacy analyses were inconclusive.
Publisher
Springer Healthcare,Springer,Springer Nature B.V,Adis, Springer Healthcare
